The Experts below are selected from a list of 64365 Experts worldwide ranked by ideXlab platform

Kerry S. Courneya - One of the best experts on this subject based on the ideXlab platform.

  • Effects of exercise dose and type during Breast Cancer Chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial
    International journal of cancer, 2019
    Co-Authors: Andria R. Morielli, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Dong-woo Kang, Kerry S. Courneya
    Abstract:

    The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during Breast Cancer Chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 Breast Cancer patients initiating Chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25-30 min of aerobic exercise (STAN; n = 96), a higher dose of 50-60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50-60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of Chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, Cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after Breast Cancer Chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone.

  • Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy
    British journal of cancer, 2014
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, James R. Vallerand, Scott C. Adams, Carolyn Proulx
    Abstract:

    Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy

  • Predictors of adherence to different types and doses of supervised exercise during Breast Cancer Chemotherapy.
    The international journal of behavioral nutrition and physical activity, 2014
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Carolyn Proulx, Roanne J. Segal, Linda Trinh, Lianne B. Dolan
    Abstract:

    Background Exercise is beneficial for Breast Cancer patients during Chemotherapy but adherence to different types and doses of exercise is a challenge. The purpose of this study was to examine predictors of adherence to different types and doses of exercise during Breast Cancer Chemotherapy in a multicenter randomized controlled trial.

  • Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Multicenter Randomized Trial
    Journal of the National Cancer Institute, 2013
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Diane Cook, Diana Jespersen, Carolyn Proulx
    Abstract:

    BACKGROUND: Exercise improves physical functioning and symptom management during Breast Cancer Chemotherapy, but the effects of different doses and types of exercise are unknown. METHODS: A multicenter trial in Canada randomized 301 Breast Cancer patients to thrice-weekly supervised exercise during Chemotherapy consisting of either a standard dose of 25 to 30 minutes of aerobic exercise (STAN; n = 96), a higher dose of 50 to 60 minutes of aerobic exercise (HIGH; n = 101), or a combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB; n = 104). The primary endpoint was physical functioning assessed by the Medical Outcomes Survey-Short Form (SF)-36. Secondary endpoints were other physical functioning scales, symptoms, fitness, and Chemotherapy completion. All statistical tests were linear mixed model analyses, and the P values were two-sided. RESULTS: Follow-up assessment of patient-reported outcomes was 99.0%. Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome. In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02). COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength. HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03). No differences emerged for body composition or Chemotherapy completion. CONCLUSIONS: A higher volume of aerobic or combined exercise is achievable and safe during Breast Cancer Chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.

  • predictors of follow up exercise behavior 6 months after a randomized trial of exercise training during Breast Cancer Chemotherapy
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Caroline Proulx, Aliya B. Ladha, Jeff K. Vallance, Roanne J. Segal
    Abstract:

    Purpose Exercise during Breast Cancer Chemotherapy is beneficial but it needs to be maintained into survivorship to optimize long-term benefits. Here, we report the predictors of follow-up exercise behavior 6 months after a randomized exercise trial in Breast Cancer patients. Methods Breast Cancer patients (N = 242) initiating adjuvant Chemotherapy were randomly assigned to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their Chemotherapy. At baseline and postintervention, data were collected on demographic, medical, behavioral, fitness, psychosocial, and motivational variables. At 6-month follow-up, participants were mailed a questionnaire that assessed exercise behavior over the past 6 months and were categorized as either meeting both aerobic and resistance exercise guidelines, either exercise guideline, or neither exercise guideline. Results Two hundred one (83.1%) participants provided 6-month follow-up data with 85 (42.3%) meeting neither exercise guideline, 74 (36.8%) meeting either exercise guideline, and 42 (20.9%) meeting both exercise guidelines. In multivariate regression analysis, seven variables independently predicted the likelihood of meeting exercise guidelines at follow-up including higher pretrial exercise (β = 0.23; P = 0.002), younger age (β = −0.15; P = 0.028), Breast conserving surgery (β = 0.15; P = 0.033), strength improvements (β = 0.15; P = 0.028), lower postintervention fatigue (β = 0.13; P = 0.067), a more positive attitude (β = 0.12; P = 0.086), and lower postintervention body mass index (β = −0.11; P = 0.105). Conclusion Exercise behavior 6 months after a randomized trial was predicted by a wide range of demographic, medical, behavioral, fitness, psychosocial, and motivational variables. These findings may help facilitate the uptake of exercise behavior during the transition from Breast Cancer patient to survivor.

Christine M. Friedenreich - One of the best experts on this subject based on the ideXlab platform.

  • Effects of exercise dose and type during Breast Cancer Chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial
    International journal of cancer, 2019
    Co-Authors: Andria R. Morielli, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Dong-woo Kang, Kerry S. Courneya
    Abstract:

    The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during Breast Cancer Chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 Breast Cancer patients initiating Chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25-30 min of aerobic exercise (STAN; n = 96), a higher dose of 50-60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50-60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of Chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, Cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after Breast Cancer Chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone.

  • Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy
    British journal of cancer, 2014
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, James R. Vallerand, Scott C. Adams, Carolyn Proulx
    Abstract:

    Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy

  • Predictors of adherence to different types and doses of supervised exercise during Breast Cancer Chemotherapy.
    The international journal of behavioral nutrition and physical activity, 2014
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Carolyn Proulx, Roanne J. Segal, Linda Trinh, Lianne B. Dolan
    Abstract:

    Background Exercise is beneficial for Breast Cancer patients during Chemotherapy but adherence to different types and doses of exercise is a challenge. The purpose of this study was to examine predictors of adherence to different types and doses of exercise during Breast Cancer Chemotherapy in a multicenter randomized controlled trial.

  • Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Multicenter Randomized Trial
    Journal of the National Cancer Institute, 2013
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Diane Cook, Diana Jespersen, Carolyn Proulx
    Abstract:

    BACKGROUND: Exercise improves physical functioning and symptom management during Breast Cancer Chemotherapy, but the effects of different doses and types of exercise are unknown. METHODS: A multicenter trial in Canada randomized 301 Breast Cancer patients to thrice-weekly supervised exercise during Chemotherapy consisting of either a standard dose of 25 to 30 minutes of aerobic exercise (STAN; n = 96), a higher dose of 50 to 60 minutes of aerobic exercise (HIGH; n = 101), or a combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB; n = 104). The primary endpoint was physical functioning assessed by the Medical Outcomes Survey-Short Form (SF)-36. Secondary endpoints were other physical functioning scales, symptoms, fitness, and Chemotherapy completion. All statistical tests were linear mixed model analyses, and the P values were two-sided. RESULTS: Follow-up assessment of patient-reported outcomes was 99.0%. Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome. In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02). COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength. HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03). No differences emerged for body composition or Chemotherapy completion. CONCLUSIONS: A higher volume of aerobic or combined exercise is achievable and safe during Breast Cancer Chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.

  • predictors of follow up exercise behavior 6 months after a randomized trial of exercise training during Breast Cancer Chemotherapy
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Caroline Proulx, Aliya B. Ladha, Jeff K. Vallance, Roanne J. Segal
    Abstract:

    Purpose Exercise during Breast Cancer Chemotherapy is beneficial but it needs to be maintained into survivorship to optimize long-term benefits. Here, we report the predictors of follow-up exercise behavior 6 months after a randomized exercise trial in Breast Cancer patients. Methods Breast Cancer patients (N = 242) initiating adjuvant Chemotherapy were randomly assigned to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their Chemotherapy. At baseline and postintervention, data were collected on demographic, medical, behavioral, fitness, psychosocial, and motivational variables. At 6-month follow-up, participants were mailed a questionnaire that assessed exercise behavior over the past 6 months and were categorized as either meeting both aerobic and resistance exercise guidelines, either exercise guideline, or neither exercise guideline. Results Two hundred one (83.1%) participants provided 6-month follow-up data with 85 (42.3%) meeting neither exercise guideline, 74 (36.8%) meeting either exercise guideline, and 42 (20.9%) meeting both exercise guidelines. In multivariate regression analysis, seven variables independently predicted the likelihood of meeting exercise guidelines at follow-up including higher pretrial exercise (β = 0.23; P = 0.002), younger age (β = −0.15; P = 0.028), Breast conserving surgery (β = 0.15; P = 0.033), strength improvements (β = 0.15; P = 0.028), lower postintervention fatigue (β = 0.13; P = 0.067), a more positive attitude (β = 0.12; P = 0.086), and lower postintervention body mass index (β = −0.11; P = 0.105). Conclusion Exercise behavior 6 months after a randomized trial was predicted by a wide range of demographic, medical, behavioral, fitness, psychosocial, and motivational variables. These findings may help facilitate the uptake of exercise behavior during the transition from Breast Cancer patient to survivor.

John R. Mackey - One of the best experts on this subject based on the ideXlab platform.

  • Effects of exercise dose and type during Breast Cancer Chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial
    International journal of cancer, 2019
    Co-Authors: Andria R. Morielli, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Dong-woo Kang, Kerry S. Courneya
    Abstract:

    The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during Breast Cancer Chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 Breast Cancer patients initiating Chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25-30 min of aerobic exercise (STAN; n = 96), a higher dose of 50-60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50-60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of Chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, Cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after Breast Cancer Chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone.

  • Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy
    British journal of cancer, 2014
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, James R. Vallerand, Scott C. Adams, Carolyn Proulx
    Abstract:

    Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy

  • Predictors of adherence to different types and doses of supervised exercise during Breast Cancer Chemotherapy.
    The international journal of behavioral nutrition and physical activity, 2014
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Carolyn Proulx, Roanne J. Segal, Linda Trinh, Lianne B. Dolan
    Abstract:

    Background Exercise is beneficial for Breast Cancer patients during Chemotherapy but adherence to different types and doses of exercise is a challenge. The purpose of this study was to examine predictors of adherence to different types and doses of exercise during Breast Cancer Chemotherapy in a multicenter randomized controlled trial.

  • Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Multicenter Randomized Trial
    Journal of the National Cancer Institute, 2013
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Diane Cook, Diana Jespersen, Carolyn Proulx
    Abstract:

    BACKGROUND: Exercise improves physical functioning and symptom management during Breast Cancer Chemotherapy, but the effects of different doses and types of exercise are unknown. METHODS: A multicenter trial in Canada randomized 301 Breast Cancer patients to thrice-weekly supervised exercise during Chemotherapy consisting of either a standard dose of 25 to 30 minutes of aerobic exercise (STAN; n = 96), a higher dose of 50 to 60 minutes of aerobic exercise (HIGH; n = 101), or a combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB; n = 104). The primary endpoint was physical functioning assessed by the Medical Outcomes Survey-Short Form (SF)-36. Secondary endpoints were other physical functioning scales, symptoms, fitness, and Chemotherapy completion. All statistical tests were linear mixed model analyses, and the P values were two-sided. RESULTS: Follow-up assessment of patient-reported outcomes was 99.0%. Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome. In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02). COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength. HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03). No differences emerged for body composition or Chemotherapy completion. CONCLUSIONS: A higher volume of aerobic or combined exercise is achievable and safe during Breast Cancer Chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.

  • predictors of follow up exercise behavior 6 months after a randomized trial of exercise training during Breast Cancer Chemotherapy
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Caroline Proulx, Aliya B. Ladha, Jeff K. Vallance, Roanne J. Segal
    Abstract:

    Purpose Exercise during Breast Cancer Chemotherapy is beneficial but it needs to be maintained into survivorship to optimize long-term benefits. Here, we report the predictors of follow-up exercise behavior 6 months after a randomized exercise trial in Breast Cancer patients. Methods Breast Cancer patients (N = 242) initiating adjuvant Chemotherapy were randomly assigned to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their Chemotherapy. At baseline and postintervention, data were collected on demographic, medical, behavioral, fitness, psychosocial, and motivational variables. At 6-month follow-up, participants were mailed a questionnaire that assessed exercise behavior over the past 6 months and were categorized as either meeting both aerobic and resistance exercise guidelines, either exercise guideline, or neither exercise guideline. Results Two hundred one (83.1%) participants provided 6-month follow-up data with 85 (42.3%) meeting neither exercise guideline, 74 (36.8%) meeting either exercise guideline, and 42 (20.9%) meeting both exercise guidelines. In multivariate regression analysis, seven variables independently predicted the likelihood of meeting exercise guidelines at follow-up including higher pretrial exercise (β = 0.23; P = 0.002), younger age (β = −0.15; P = 0.028), Breast conserving surgery (β = 0.15; P = 0.033), strength improvements (β = 0.15; P = 0.028), lower postintervention fatigue (β = 0.13; P = 0.067), a more positive attitude (β = 0.12; P = 0.086), and lower postintervention body mass index (β = −0.11; P = 0.105). Conclusion Exercise behavior 6 months after a randomized trial was predicted by a wide range of demographic, medical, behavioral, fitness, psychosocial, and motivational variables. These findings may help facilitate the uptake of exercise behavior during the transition from Breast Cancer patient to survivor.

Karen A. Gelmon - One of the best experts on this subject based on the ideXlab platform.

  • Effects of exercise dose and type during Breast Cancer Chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial
    International journal of cancer, 2019
    Co-Authors: Andria R. Morielli, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Dong-woo Kang, Kerry S. Courneya
    Abstract:

    The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during Breast Cancer Chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 Breast Cancer patients initiating Chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25-30 min of aerobic exercise (STAN; n = 96), a higher dose of 50-60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50-60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of Chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, Cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after Breast Cancer Chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone.

  • Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy
    British journal of cancer, 2014
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, James R. Vallerand, Scott C. Adams, Carolyn Proulx
    Abstract:

    Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy

  • Predictors of adherence to different types and doses of supervised exercise during Breast Cancer Chemotherapy.
    The international journal of behavioral nutrition and physical activity, 2014
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Carolyn Proulx, Roanne J. Segal, Linda Trinh, Lianne B. Dolan
    Abstract:

    Background Exercise is beneficial for Breast Cancer patients during Chemotherapy but adherence to different types and doses of exercise is a challenge. The purpose of this study was to examine predictors of adherence to different types and doses of exercise during Breast Cancer Chemotherapy in a multicenter randomized controlled trial.

  • Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Multicenter Randomized Trial
    Journal of the National Cancer Institute, 2013
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Diane Cook, Diana Jespersen, Carolyn Proulx
    Abstract:

    BACKGROUND: Exercise improves physical functioning and symptom management during Breast Cancer Chemotherapy, but the effects of different doses and types of exercise are unknown. METHODS: A multicenter trial in Canada randomized 301 Breast Cancer patients to thrice-weekly supervised exercise during Chemotherapy consisting of either a standard dose of 25 to 30 minutes of aerobic exercise (STAN; n = 96), a higher dose of 50 to 60 minutes of aerobic exercise (HIGH; n = 101), or a combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB; n = 104). The primary endpoint was physical functioning assessed by the Medical Outcomes Survey-Short Form (SF)-36. Secondary endpoints were other physical functioning scales, symptoms, fitness, and Chemotherapy completion. All statistical tests were linear mixed model analyses, and the P values were two-sided. RESULTS: Follow-up assessment of patient-reported outcomes was 99.0%. Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome. In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02). COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength. HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03). No differences emerged for body composition or Chemotherapy completion. CONCLUSIONS: A higher volume of aerobic or combined exercise is achievable and safe during Breast Cancer Chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.

  • predictors of follow up exercise behavior 6 months after a randomized trial of exercise training during Breast Cancer Chemotherapy
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Caroline Proulx, Aliya B. Ladha, Jeff K. Vallance, Roanne J. Segal
    Abstract:

    Purpose Exercise during Breast Cancer Chemotherapy is beneficial but it needs to be maintained into survivorship to optimize long-term benefits. Here, we report the predictors of follow-up exercise behavior 6 months after a randomized exercise trial in Breast Cancer patients. Methods Breast Cancer patients (N = 242) initiating adjuvant Chemotherapy were randomly assigned to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their Chemotherapy. At baseline and postintervention, data were collected on demographic, medical, behavioral, fitness, psychosocial, and motivational variables. At 6-month follow-up, participants were mailed a questionnaire that assessed exercise behavior over the past 6 months and were categorized as either meeting both aerobic and resistance exercise guidelines, either exercise guideline, or neither exercise guideline. Results Two hundred one (83.1%) participants provided 6-month follow-up data with 85 (42.3%) meeting neither exercise guideline, 74 (36.8%) meeting either exercise guideline, and 42 (20.9%) meeting both exercise guidelines. In multivariate regression analysis, seven variables independently predicted the likelihood of meeting exercise guidelines at follow-up including higher pretrial exercise (β = 0.23; P = 0.002), younger age (β = −0.15; P = 0.028), Breast conserving surgery (β = 0.15; P = 0.033), strength improvements (β = 0.15; P = 0.028), lower postintervention fatigue (β = 0.13; P = 0.067), a more positive attitude (β = 0.12; P = 0.086), and lower postintervention body mass index (β = −0.11; P = 0.105). Conclusion Exercise behavior 6 months after a randomized trial was predicted by a wide range of demographic, medical, behavioral, fitness, psychosocial, and motivational variables. These findings may help facilitate the uptake of exercise behavior during the transition from Breast Cancer patient to survivor.

Robert D. Reid - One of the best experts on this subject based on the ideXlab platform.

  • Effects of exercise dose and type during Breast Cancer Chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial
    International journal of cancer, 2019
    Co-Authors: Andria R. Morielli, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Dong-woo Kang, Kerry S. Courneya
    Abstract:

    The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during Breast Cancer Chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 Breast Cancer patients initiating Chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25-30 min of aerobic exercise (STAN; n = 96), a higher dose of 50-60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50-60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of Chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, Cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after Breast Cancer Chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone.

  • Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy
    British journal of cancer, 2014
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, James R. Vallerand, Scott C. Adams, Carolyn Proulx
    Abstract:

    Subgroup effects in a randomised trial of different types and doses of exercise during Breast Cancer Chemotherapy

  • Predictors of adherence to different types and doses of supervised exercise during Breast Cancer Chemotherapy.
    The international journal of behavioral nutrition and physical activity, 2014
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Carolyn Proulx, Roanne J. Segal, Linda Trinh, Lianne B. Dolan
    Abstract:

    Background Exercise is beneficial for Breast Cancer patients during Chemotherapy but adherence to different types and doses of exercise is a challenge. The purpose of this study was to examine predictors of adherence to different types and doses of exercise during Breast Cancer Chemotherapy in a multicenter randomized controlled trial.

  • Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Multicenter Randomized Trial
    Journal of the National Cancer Institute, 2013
    Co-Authors: Kerry S. Courneya, Donald C. Mckenzie, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Yutaka Yasui, Robert D. Reid, Diane Cook, Diana Jespersen, Carolyn Proulx
    Abstract:

    BACKGROUND: Exercise improves physical functioning and symptom management during Breast Cancer Chemotherapy, but the effects of different doses and types of exercise are unknown. METHODS: A multicenter trial in Canada randomized 301 Breast Cancer patients to thrice-weekly supervised exercise during Chemotherapy consisting of either a standard dose of 25 to 30 minutes of aerobic exercise (STAN; n = 96), a higher dose of 50 to 60 minutes of aerobic exercise (HIGH; n = 101), or a combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB; n = 104). The primary endpoint was physical functioning assessed by the Medical Outcomes Survey-Short Form (SF)-36. Secondary endpoints were other physical functioning scales, symptoms, fitness, and Chemotherapy completion. All statistical tests were linear mixed model analyses, and the P values were two-sided. RESULTS: Follow-up assessment of patient-reported outcomes was 99.0%. Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome. In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02). COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength. HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03). No differences emerged for body composition or Chemotherapy completion. CONCLUSIONS: A higher volume of aerobic or combined exercise is achievable and safe during Breast Cancer Chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.

  • predictors of follow up exercise behavior 6 months after a randomized trial of exercise training during Breast Cancer Chemotherapy
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Kerry S. Courneya, John R. Mackey, Karen A. Gelmon, Christine M. Friedenreich, Robert D. Reid, Caroline Proulx, Aliya B. Ladha, Jeff K. Vallance, Roanne J. Segal
    Abstract:

    Purpose Exercise during Breast Cancer Chemotherapy is beneficial but it needs to be maintained into survivorship to optimize long-term benefits. Here, we report the predictors of follow-up exercise behavior 6 months after a randomized exercise trial in Breast Cancer patients. Methods Breast Cancer patients (N = 242) initiating adjuvant Chemotherapy were randomly assigned to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their Chemotherapy. At baseline and postintervention, data were collected on demographic, medical, behavioral, fitness, psychosocial, and motivational variables. At 6-month follow-up, participants were mailed a questionnaire that assessed exercise behavior over the past 6 months and were categorized as either meeting both aerobic and resistance exercise guidelines, either exercise guideline, or neither exercise guideline. Results Two hundred one (83.1%) participants provided 6-month follow-up data with 85 (42.3%) meeting neither exercise guideline, 74 (36.8%) meeting either exercise guideline, and 42 (20.9%) meeting both exercise guidelines. In multivariate regression analysis, seven variables independently predicted the likelihood of meeting exercise guidelines at follow-up including higher pretrial exercise (β = 0.23; P = 0.002), younger age (β = −0.15; P = 0.028), Breast conserving surgery (β = 0.15; P = 0.033), strength improvements (β = 0.15; P = 0.028), lower postintervention fatigue (β = 0.13; P = 0.067), a more positive attitude (β = 0.12; P = 0.086), and lower postintervention body mass index (β = −0.11; P = 0.105). Conclusion Exercise behavior 6 months after a randomized trial was predicted by a wide range of demographic, medical, behavioral, fitness, psychosocial, and motivational variables. These findings may help facilitate the uptake of exercise behavior during the transition from Breast Cancer patient to survivor.